Cognizant And Boehringer Ingelheim Launch Unified Digital Platform To Streamline Drug Development

Cognizant and Boehringer Ingelheim have officially launched a new end-to-end technology platform powered by the Veeva Development Cloud, marking the successful completion of the first phase of their collaboration. This initiative is designed to modernise Boehringer’s drug development processes by replacing over 20 legacy platforms with a unified "One Medicine Platform." The goal is to streamline operations, improve cross-functional collaboration, and enhance overall efficiency in medicinal development.

"For years, Boehringer Ingelheim used multiple vendor systems which could not communicate with each other, which led to complex workflows. The launch of our One Medicine Platform revolutionizes our medicinal development processes and takes our operational efficiencies to the next level," commented Oliver Fink, Head Learning, Processes & Digitalization, Global Quality Medicine at Boehringer Ingelheim.

As the lead system integrator, Cognizant was pivotal in leading platform development by co-creating roadmap designs and implementing an agile framework. Cognizant leads system integration activities while delivering multiple project services, including program management and system design, followed by integration functions, data migration, and testing with validation completion. Cognizant collaborated with Syneos Health Consulting for business process engineering and worked with Veeva to configure and optimise the system’s architecture.

Gagan Syal, Head of Life Sciences, EMEA & APAC, at Cognizant, commented, "We are pleased to achieve this program milestone in our collaboration with Boehringer Ingelheim. With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams, we have executed this project in record time."

The implementation's first phase brought together clinical data, clinical operations, and regulatory and quality functions, reaching more than 15,000 users involved in clinical development. The following phase of Boehringer’s system implementation aims to strengthen clinical operations through additional system modules while expanding the company's regulatory function during Phase Two.